<DOC>
	<DOCNO>NCT00278174</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth tumor cell slow growth kidney cancer . PURPOSE : This phase II trial study well interferon alfa work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Interferon Alfa ( IFN-Alpha-1b ) Renal Cancer With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient metastatic renal clear cell carcinoma treat interferon alfa-1b . Secondary - Determine toxicity drug patient . OUTLINE : This open-label study . Patients receive interferon alfa-1b subcutaneously daily . Treatment continue absence unacceptable toxicity disease progression . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm predominantly renal clear cell carcinoma Clinical evidence OR biopsyproven metastatic disease site sit distant primary tumor Must measurable disease , define ≥ 1 unidimensionally measurable lesion measure ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Good intermediaterisk category define ≤ 2 follow factor : Time initial diagnosis treatment &lt; 1 year Karnofsky performance status &lt; 80 % Hemoglobin &lt; low limit normal Corrected calcium &gt; 10.0 mg/dL Lactate dehydrogenase ( LDH ) &gt; 1.5 time upper limit normal ( ULN ) No major clinical ascites pleural effusion No CNS metastases neurologic exam CT scan MRI PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 3 month WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.5 g/dL Creatinine ≤ 1.5 mg/dL ( 2.0 mg/dL postnephrectomy patient ) Calcium normal Total bilirubin ≤ 1.5 mg/dL AST ≤ 3.0 time normal Alkaline phosphatase ≤ 2.5 time normal ( 10 time ULN presence bone metastasis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior duration study treatment No history serious cardiac arrhythmia , congestive heart failure , angina pectoris , severe cardiovascular disease ( i.e. , New York Heart Association class III IV ) No know positivity HIV hepatitis B surface antigen No history seizure disorder No local and/or systemic infection require antibiotic within 28 day prior study entry No malignancy except basal cell squamous cell carcinoma skin , carcinoma situ uterine cervix , malignancy treat curative intent complete remission &gt; 3 year PRIOR CONCURRENT THERAPY : No prior organ allografts No prior interferon No prior cytokinebased therapy metastatic disease Prior radiotherapy allow control pain skeletal lesion provide treatment complete &gt; 28 day prior study entry patient recover No major surgery require general anesthesia within 28 day prior study entry No 2 prior therapy metastatic disease No concurrent palliative radiotherapy No concurrent chemotherapy No concurrent hormonal therapy except hormone administer nondiseaserelated condition ( e.g. , insulin diabetes ) No concurrent steroid use except ongoing replacement therapy physiologic dos corticosteroids No concurrent dexamethasone steroidal antiemetic antiinflammatories No concurrent anticancer therapy No concurrent aspirin barbiturates No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
</DOC>